bpc 157 oral vs injection research orally BPC-157 100 × 500mcg - 129€ BPC-157 Oral vs Injection: Benefits,

The latter results from a decrease in the synthesis of haptocorrin and possibly hemodilution

Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies

Many patients report changes within 4-8 weeks, with continued improvement over several months

It does one thing well - enhances fat mobilization and oxidation without affecting blood sugar, hormones, or appetite

2014, 72 sup K2 Kolhouse et al

Side effects are uncommon but may include mild discomfort or bruising at the injection site and occasional lightheadedness